Short answer
RET testing in medullary thyroid cancer only becomes useful when you separate the report into the right track. A germline result speaks to inherited MEN2 risk and family follow-up. A tumor-only result speaks to the cancer itself. A paired tumor-normal report can separate the two. A VUS is still uncertain. Once you know which lane you are in, the next step is usually clearer: genetics review, targeted family testing, surveillance planning, or tumor-focused care.
Start with the report kind
| Report wording | What it usually means | Best next question |
|---|---|---|
| Positive germline RET pathogenic or likely pathogenic variant | Inherited MEN2 risk is on the table. | Who in the family needs targeted testing and surveillance? |
| Negative germline RET result | Inherited RET-related MEN2 is less likely. | Was the assay broad enough for the clinical question? |
| RET VUS | The lab found a change but cannot call it disease-causing yet. | Who will watch for reclassification? |
| Tumor-only RET finding | The change may be limited to the cancer. | Does germline confirmation still matter? |
| Paired tumor-normal result | The normal comparator helps separate inherited from somatic findings. | Which result should guide family counseling? |
| Known family RET variant | The family already knows the exact change. | Is this targeted family testing for that exact variant? |
If germline RET is negative
A negative germline RET result lowers the chance of inherited MEN2, but it does not automatically close the case. MedlinePlus notes that some tests can miss disease-causing changes, and GeneReviews stresses that an apparently negative family history or a negative result should still be read with the clinical picture. NCI also notes that RET testing is recommended for all MTC because some cases with no family history still carry inherited risk.
That is why a negative result is best treated as “lower concern” rather than “nothing else to do.” If the report was limited, if the family history is suspicious, or if the result is being used to decide family screening, the safer next step is genetics review.
If the result is uncertain or a VUS
A RET variant of uncertain significance is not a confirmed MEN2 result. It should not usually be used as the family’s known pathogenic variant, and it should not be treated like a positive result until the lab reclassifies it. The right move is usually to track the reclassification plan, review the family history, and avoid overcalling the result for relatives.
If the report is tumor-only or paired tumor-normal
- Tumor-only testing asks what is inside the cancer itself.
- Germline testing asks whether the change is in normal cells and could be inherited.
- Paired tumor-normal testing helps sort out somatic-only findings from inherited ones.
- A tumor-only RET finding can be useful for tumor biology without proving family risk.
That split matters because medullary thyroid cancer can be sporadic or hereditary, and the same RET name in a report does not automatically mean the same thing for the family.
If a known family variant already exists
When a family already has a confirmed RET pathogenic variant, the best next step is usually targeted family testing for that exact change, not a broad re-screening exercise. GeneReviews recommends testing at-risk relatives when the familial RET variant is known, and pediatric testing can happen early when the result changes childhood screening or preventive timing.
If the relative is positive for the known family variant, the pathway usually shifts toward MEN2 surveillance planning. If the relative is truly negative for the known family variant, that can be reassuring for that branch of the family, but the exact report still needs to be read in context.
Questions to ask
- Was the RET result germline, tumor-only, or paired tumor-normal?
- Did the lab test the exact family variant or a broader gene region?
- Was deletion/duplication analysis included if that mattered for the question?
- Who will decide whether a VUS gets reclassified later?
- Does the result change thyroid surgery timing, calcitonin follow-up, adrenal screening, or family cascade testing?
FAQ
What should I check first in a RET report?
Check whether the test is germline, tumor-only, or paired tumor-normal, because those three report types answer different questions.
Does a negative germline RET result rule out MEN2?
It lowers inherited RET-related MEN2 concern, but the exact assay scope, the clinical picture, and the family history still matter.
What does a RET VUS mean here?
A variant of uncertain significance is not a confirmed MEN2 result and usually should not be used for family cascade testing unless it is reclassified later.
Why does tumor-only RET testing not settle family risk?
Tumor-only testing can find somatic changes in the cancer, but it does not prove whether the same change is present in normal cells and could be inherited.
Can a family variant be tested in children?
Yes, when the known family RET variant changes childhood screening or preventive timing, children may need targeted testing earlier than many other genetic conditions.
When should a genetics team get involved?
Genetics review is useful when the report is unclear, when the assay may have been limited, or when the result changes family testing, thyroid surgery timing, or adrenal screening.
Related guides: Negative RET testing with medullary thyroid cancer, RET tumor-only vs germline follow-up, MEN2 family variant testing, and RET result follow-up roadmap.